How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/complicated-skin-and-skin-structure-enterococcus-faecalis-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Complicated Skin and Skin Structure Enterococcus Faecalis Infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Complicated Skin and Skin Structure Enterococcus Faecalis Infection (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Complicated Skin and Skin Structure Enterococcus Faecalis Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Vibativ	TELAVANCIN HYDROCHLORIDE	Cumberland	Lipoglycopeptide Antibacterial		2009-01-01
Vibativ	TELAVANCIN	Cumberland	Lipoglycopeptide Antibacterial		2009-01-01
Tygacil	TIGECYCLINE	Fresenius Kabi	Tetracycline-class Antibacterial [EPC]	30S ribosomal subunit	2005-01-01
Cubicin	Daptomycin	Baxter	lipopeptide antibacterial		2003-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Cubicin	Cubicin	Clinical Alliance for Research & Education - Infectious Diseases, LLC.		Outer membrane porin protein OmpD
DAPT	DAPT	Baxter Hlthcare Corp		Outer membrane porin protein OmpD
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Cumberland · 2 drugs in Complicated Skin and Skin Structure Enterococcus Faecalis Infection
· 2 drugs in Complicated Skin and Skin Structure Enterococcus Faecalis Infection
Baxter · 1 drug in Complicated Skin and Skin Structure Enterococcus Faecalis Infection
Baxter Hlthcare Corp · 1 drug in Complicated Skin and Skin Structure Enterococcus Faecalis Infection
Clinical Alliance for Research & Education - Infectious Diseases, LLC. · 1 drug in Complicated Skin and Skin Structure Enterococcus Faecalis Infection
Fresenius Kabi · 1 drug in Complicated Skin and Skin Structure Enterococcus Faecalis Infection
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Complicated Skin and Skin Structure Enterococcus Faecalis Infection
Pfizer · 1 drug in Complicated Skin and Skin Structure Enterococcus Faecalis Infection
Assistance Publique - Hôpitaux de Paris · 1 drug in Complicated Skin and Skin Structure Enterococcus Faecalis Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Complicated Skin and Skin Structure Enterococcus Faecalis Infection:

Cite this brief

Drug Landscape (2026). Complicated Skin and Skin Structure Enterococcus Faecalis Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/complicated-skin-and-skin-structure-enterococcus-faecalis-infection. Accessed 2026-06-11.

Complicated Skin and Skin Structure Enterococcus Faecalis Infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing